Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation
NCT01463956
Blood-Borne Infections, Communicable Diseases
Bordeaux, France
View Trial DetailsNCT Number: NCT00893308
Patients' metabolic properties may affect their immune response. This study aims to assess the effect of hosts' metabolic properties to viral infection.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Blood samples were drawn from patients with Gaucher disease and healthy individuals, with and without HCV. Blood samples were tested for protein specific T cell proliferation, IFNg and IL-10 using ELISPOT assays, serum IFNg, IL-2, IL-6, IL-10 and IL-4 levels. FACS analysis was used for evaluation of lymphocytes subsets.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hadassah Medical Organization
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01463956
Blood-Borne Infections, Communicable Diseases
Bordeaux, France
View Trial DetailsNCT04134767
Blood-Borne Infections, Chemically-Induced Disorders
Lexington, Kentucky, United States
View Trial DetailsNCT03379506
Blood-Borne Infections, Communicable Diseases
San Francisco, California, United States
View Trial DetailsNCT04008927
Blood-Borne Infections, Communicable Diseases
Montpellier, France
View Trial Details